NASDAQ:HCM - HUTCHISON CHINA/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$29.36 -0.31 (-1.04 %)
(As of 08/19/2018 02:15 AM ET)
Previous Close$29.36
Today's Range$29.04 - $31.15
52-Week Range$22.90 - $42.25
Volume43,517 shs
Average Volume103,773 shs
Market Capitalization$4.37 billion
P/E Ratio-133.45
Dividend YieldN/A
Beta0.12
HUTCHISON CHINA/S logoHutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HCM
CUSIPN/A
Phone852-2121-3888

Debt

Debt-to-Equity Ratio0.06
Current Ratio4.67
Quick Ratio4.55

Price-To-Earnings

Trailing P/E Ratio-133.45
Forward P/E Ratio-94.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$241.20 million
Price / Sales16.18
Cash FlowN/A
Price / CashN/A
Book Value$3.65 per share
Price / Book8.04

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees590
Outstanding Shares132,950,000
Market Cap$4.37 billion

HUTCHISON CHINA/S (NASDAQ:HCM) Frequently Asked Questions

What is HUTCHISON CHINA/S's stock symbol?

HUTCHISON CHINA/S trades on the NASDAQ under the ticker symbol "HCM."

What price target have analysts set for HCM?

2 equities research analysts have issued 12 month price objectives for HUTCHISON CHINA/S's shares. Their predictions range from $38.00 to $38.00. On average, they expect HUTCHISON CHINA/S's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price. View Analyst Price Targets for HUTCHISON CHINA/S.

What is the consensus analysts' recommendation for HUTCHISON CHINA/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHISON CHINA/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HUTCHISON CHINA/S.

Who are some of HUTCHISON CHINA/S's key competitors?

Who are HUTCHISON CHINA/S's key executives?

HUTCHISON CHINA/S's management team includes the folowing people:
  • Mr. Chi Keung To BSc, ACGI, MBA, Exec. Chairman (Age 66)
  • Mr. Christian Hogg BSc, MBA, CEO & Exec. Director (Age 52)
  • Mr. Johnny Cheng BEc, CA, CFO & Exec. Director (Age 51)
  • Dr. Weiguo Su Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 61)
  • Ms. Edith Shih BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 66)

When did HUTCHISON CHINA/S IPO?

(HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

Has HUTCHISON CHINA/S been receiving favorable news coverage?

Press coverage about HCM stock has trended positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. HUTCHISON CHINA/S earned a media and rumor sentiment score of 0.42 on Accern's scale. They also assigned news articles about the company an impact score of 47.67 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for HUTCHISON CHINA/S.

Who are HUTCHISON CHINA/S's major shareholders?

HUTCHISON CHINA/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include OppenheimerFunds Inc. (2.24%), Bellevue Group AG (0.25%), GSA Capital Partners LLP (0.17%), Alps Advisors Inc. (0.14%), Sumitomo Mitsui Trust Holdings Inc. (0.09%) and State of New Jersey Common Pension Fund D (0.07%).

Which institutional investors are selling HUTCHISON CHINA/S stock?

HCM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC and Citadel Advisors LLC.

Which institutional investors are buying HUTCHISON CHINA/S stock?

HCM stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Alps Advisors Inc., State of New Jersey Common Pension Fund D, Bellevue Group AG, GSA Capital Partners LLP and Sumitomo Mitsui Trust Holdings Inc..

How do I buy shares of HUTCHISON CHINA/S?

Shares of HCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is HUTCHISON CHINA/S's stock price today?

One share of HCM stock can currently be purchased for approximately $29.36.

How big of a company is HUTCHISON CHINA/S?

HUTCHISON CHINA/S has a market capitalization of $4.37 billion and generates $241.20 million in revenue each year. The company earns $-26,730,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. HUTCHISON CHINA/S employs 590 workers across the globe.

How can I contact HUTCHISON CHINA/S?

HUTCHISON CHINA/S's mailing address is 22ND FLOOR HUTCHISON HOUSE 10 HARCOURT ROAD, HONG KONG K3, . The company can be reached via phone at 852-2121-3888 or via email at [email protected]


MarketBeat Community Rating for HUTCHISON CHINA/S (NASDAQ HCM)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about HUTCHISON CHINA/S and other stocks. Vote "Outperform" if you believe HCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Featured Article: Asset Allocation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.